What Did STAR*D Teach Us? Results From a Large-Scale, Practical, Clinical Trial for Patients With Depression
The DOI matches its Crossref record.
Abstract
The authors provide an overview of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study (www.star-d.org), a large-scale practical clinical trial to determine which of several treatments are the most effective "next-steps" for patients with major depressive disorder whose symptoms do not remit or who cannot tolerate an initial treatment and, if needed, ensuing treatments. Entry criteria were broadly defined and inclusive, and patients were enrolled from psychiatric and primary care clinics. All participants began on citalopram and were managed by clinic physicians, who followed an algorithm-guided acute-phase treatment through five visits over 12 weeks. At the end of each sequence, patients whose depression had not fully remitted were eligible for subsequent randomized trials in a sequence of up to three clinical trials. In general, remission rates in the study clinics were lower than expected, suggesting the need for several steps to achieve remission for most patients. There was no clear medication "winner" for patients whose depression did not remit after one or more aggressive medication trials. Both switching and augmenting appeared to be reasonable options when an initial antidepressant treatment failed, although these two strategies could not be directly compared. Further, the likelihood of remission after two vigorous medication trials substantially decreased, and remission would likely require more complicated medication regimens for which the existing evidence base is quite thin. STAR*D demonstrated that inclusion of more real-world patients in clinical trials is both feasible and informative. Policy implications of the findings, as well as the study's limitations, are discussed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“low efficacy (only 27% of depressed patients achieved remission after 12 weeks of citalopram treatment as measured by HAM-D)”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [259]
In the citing paper
“the current standard of care treatments suffer from slow onset (e.g., 7 week average response time with citalopram)”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [259]
In the citing paper
“Studies examining antidepressant efficacy reveal 30% of depressed patients fail to respond to common antidepressant treatment (1)”
From Emerging Role for Nucleus Accumbens Medium Spiny Neuron Subtypes in Depression (2017) · cites this paper as [1]
In the citing paper
“Currently available antidepressant medications, alone and in combination, are associated with high rates of partial- or non-response, delayed response onset of weeks to months, and limited duration of efficacy5.”
From Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants (2016) · cites this paper as [5]
In the citing paper
“while more than a third fail to achieve remission even after several rounds of treatment ( Al-Harbi, 2012 , Gaynes et al., 2009 , Strawbridge et al., 2022 )”
From Self-blame-selective hyper-connectivity between anterior temporal and subgenual cortices predicts prognosis in major depressive disorder (2023) · cites this paper as Gaynes et al., 2009
Citations
Cites
Still being checked.
Cited by
Items 101–200 of 764
A systematic review of fMRI neurofeedback reporting and effects in clinical populations
Tursic, A., Eck, J., Lührs, M., Linden, D. E. J., & Goebel, R. (2020) · NeuroImage Clinical · doi:10.1016/j.nicl.2020.102496 · Cited by 77
Rosenblat, J. D., Husain, M. I., Lee, Y. L., McIntyre, R. S., Mansur, R. B., Castle, D. J., Offman, H., Parikh, S. V., Frey, B. N., Schaffer, A., et al. (2022) · The Canadian Journal of Psychiatry · doi:10.1177/07067437221111371 · Cited by 76
A unified model of ketamine’s dissociative and psychedelic properties
Marguilho, M., Figueiredo, I., & Castro-Rodrigues, P. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221140011 · Cited by 78
Berk, M., Berk, L., Udina, M., Moylan, S., Stafford, L., Hallam, K., Goldstone, S., & McGorry, P. D. (2012) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867411432072 · Cited by 68
Beyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive Review
D. Rosenblat, J., S. McIntyre, R., S. Alves, G., N. Fountoulakis, K., & F. Carvalho, A. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150630175044 · Cited by 71
The influence of ketamine on drug discovery in depression
Kraus, C., Wasserman, D., Henter, I. D., Acevedo-Diaz, E., Kadriu, B., & Zarate, C. A. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.07.007 · Cited by 75
“Currently available standard antidepressants, which are mostly monoaminergic-based, are effective for a large proportion of patients; however, a significant subset do not respond to these agents [3].”
BackgroundBeyond the neuron: Role of non-neuronal cells in stress disorders
Cathomas, F., Holt, L. M., Parise, E. M., Liu, J., Murrough, J. W., Casaccia, P., Nestler, E. J., & Russo, S. J. (2022) · Neuron · doi:10.1016/j.neuron.2022.01.033 · Cited by 76
Gao, W., Wang, W., Liu, G., Zhang, J., Yang, J. M., & Deng, Z. (2018) · Metabolic Brain Disease · doi:10.1007/s11011-018-0342-z · Cited by 71
Gauthier, G., Guérin, A., Zhdanava, M., Jacobson, W., Nomikos, G., Merikle, E., François, C., & Perez, V. (2017) · BMC Psychiatry · doi:10.1186/s12888-017-1385-0 · Cited by 70
Management of Treatment-Resistant Depression
Keitner, G. I., & Mansfield, A. K. (2011) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2011.11.004 · Cited by 70
Li, Y., Wang, L., Wang, P., Fan, C., Zhang, P., Shen, J., & Yu, S. Y. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/2325391 · Cited by 69
Shen, M., Yang, Y., Wu, Y., Zhang, B., Wu, H., Wang, L., Tang, H., & Chen, J. (2019) · Phytotherapy Research · doi:10.1002/ptr.6237 · Cited by 68
“c tricyclic antidepressants, selective serotonin (5‐HT) reuptake inhibitors, and norepinephrine (NE) reuptake inhibitors, elicit some undesirable side effects (Gaynes et al., 2009; Kennedy, 2006; Nemeroff, 2007).”
BackgroundHeerlein, K., Young, A. H., Otte, C., Frodl, T., Degraeve, G., Hagedoorn, W., Oliveira-Maia, A. J., Perez Sola, V., Rathod, S., Rosso, G., et al. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.11.124 · Cited by 56
Rapid Acting Antidepressants in Chronic Stress Models: Molecular and Cellular Mechanisms
Hare, B. D., Ghosal, S., & Duman, R. S. (2017) · Chronic Stress · doi:10.1177/2470547017697317 · Cited by 67
Humanistic outcomes in treatment resistant depression: a secondary analysis of the STAR*D study
DiBernardo, A., Lin, X., Zhang, Q., Xiang, J., Lu, L., Jamieson, C., Benson, C., Lee, K., Bodén, R., Brandt, L., et al. (2018) · BMC Psychiatry · doi:10.1186/s12888-018-1920-7 · Cited by 66
Clinical Implications of the STAR*D Trial
Rush, A. J., & Jain, S. K. (2018) · Handbook of experimental pharmacology · doi:10.1007/164_2018_153 · Cited by 65
Self-citationModulation of amygdala reactivity following rapidly acting interventions for major depression
Loureiro, J. R. A., Leaver, A., Vasavada, M., Sahib, A. K., Kubicki, A., Joshi, S., Woods, R. P., Wade, B., Congdon, E., Espinoza, R., et al. (2020) · Human Brain Mapping · doi:10.1002/hbm.24895 · Cited by 64
Porcelli, S., Kasper, S., Zohar, J., Souery, D., Montgomery, S., Ferentinos, P. P., Rujescu, D., Mendlewicz, J., Pich, E. M., Pollentier, S., et al. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.109835 · Cited by 64
Katzelnick, D. J., Duffy, F. F., Chung, H., Regier, D. A., Rae, D. S., & Trivedi, M. H. (2011) · Psychiatric Services · doi:10.1176/ps.62.8.pss6208_0929 · Cited by 56
Self-citationHighland, J. N., Morris, P. J., Zanos, P., Lovett, J., Ghosh, S., Wang, A. Q., Zarate, C. A., Thomas, C. J., Moaddel, R., & Gould, T. D. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881118812095 · Cited by 62
“…superior to that of classical antidepressants – which typically require weeks to take effect and are ineffective in a large number of patients (Gaynes et al., 2009; Insel and Wang, 2009) – the widespread use of ketamine as an antidepressant is limited by its dissociative side effects and…”
Trigeminal Nerve Stimulation: Seminal Animal and Human Studies for Epilepsy and Depression
DeGiorgio, C. M., Fanselow, E. E., Schrader, L. M., & Cook, I. A. (2011) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2011.07.001 · Cited by 62
Simvastatin prevents and ameliorates depressive behaviors via neuroinflammatory regulation in mice
Yu, X.-B., Zhang, H.-N., Dai, Y., Zhou, Z.-Y., Xu, R.-A., Hu, L.-F., Zhang, C.-H., Xu, H.-Q., An, Y.-Q., Tang, C.-R., et al. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.11.086 · Cited by 62
Kheirabadi, D., Kheirabadi, G. R., Mirlohi, Z., Tarrahi, M. J., & Norbaksh, A. (2020) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001289 · Cited by 63
Hoertel, N., Le Strat, Y., Blanco, C., Lavaud, P., & Dubertret, C. (2012) · Depression and Anxiety · doi:10.1002/da.21937 · Cited by 61
Metabolic and Microbiota Measures as Peripheral Biomarkers in Major Depressive Disorder
Horne, R. G., & Foster, J. A. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00513 · Cited by 61
Strategies to Prolong Ketamine’s Efficacy in Adults with Treatment-Resistant Depression
McMullen, E. P., Lee, Y. L., Lipsitz, O., Lui, L. M. W., Vinberg, M., Ho, R., Rodrigues, N. B., Rosenblat, J. D., Cao, B., Gill, H., et al. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01732-8 · Cited by 60
Neuroimaging and Psychiatry: The Long Road from Bench to Bedside
Mayberg, H. S. (2014) · Hastings Center Report · doi:10.1002/hast.296 · Cited by 49
Resting State Functional Connectivity Biomarkers of Treatment Response in Mood Disorders: A Review
Taylor, J. J., Kurt, H. G., & Anand, A. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.565136 · Cited by 58
Li, L., Su, Y., Wu, Y., Castellanos, F. X., Li, K., Li, J., Si, T., & Yan, C. (2021) · Human Brain Mapping · doi:10.1002/hbm.25391 · Cited by 58
Galletly, C., Gill, S., Clarke, P., Burton, C., & Fitzgerald, P. B. (2012) · Psychological Medicine · doi:10.1017/s0033291711001760 · Cited by 54
Falk, E., Schlieper, D., van Caster, P., Lutterbeck, M. J., Schwartz, J., Cordes, J., Grau, I., Kienbaum, P., & Neukirchen, M. (2020) · BMC Palliative Care · doi:10.1186/s12904-019-0499-1 · Cited by 57
Oliveira-Maia, A. J., Bobrowska, A., Constant, É., Ito, T., Kambarov, Y., Luedke, H., Mulhern-Haughey, S., & von Holt, C. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02700-0 · Cited by 57
Gálvez, J. F., Keser, Z., Mwangi, B., Ghouse, A. A., Fenoy, A. J., Schulz, P. E., Sanches, M., Quevedo, J., Selvaraj, S., Gajwani, P., et al. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.12.003 · Cited by 57
Subbaiah, M. A. M. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01827 · Cited by 56
Jog, M., Wang, D. J. J., & Narr, K. L. (2019) · Personalized Medicine in Psychiatry · doi:10.1016/j.pmip.2019.03.001 · Cited by 56
Kappelmann, N., Rein, M., Fietz, J., Mayberg, H. S., Craighead, W. E., Dunlop, B. W., Nemeroff, C. B., Keller, M. B., Klein, D. N., Arnow, B. A., et al. (2020) · BMC Medicine · doi:10.1186/s12916-020-01623-9 · Cited by 57
Blood miR-144-3p: a novel diagnostic and therapeutic tool for depression
van der Zee, Y. Y., Eijssen, L., Mews, P., Ramakrishnan, A., Alvarez, K., Lardner, C. K., Cates, H. M., Walker, D. M., Torres‐Berrío, A., Browne, C. J., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01712-6 · Cited by 56
Inhibition of a Descending Prefrontal Circuit Prevents Ketamine-Induced Stress Resilience in Females
Dolzani, S. D., Baratta, M. V., Moss, J. M., Leslie, N. L., Tilden, S. G., Sørensen, A. T., Watkins, L. R., Lin, Y., & Maier, S. F. (2018) · eneuro · doi:10.1523/eneuro.0025-18.2018 · Cited by 50
Okubo, R., Hasegawa, T., Fukuyama, K., Shiroyama, T., & Okada, M. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.623684 · Cited by 55
Brain-based mechanisms of late-life depression: Implications for novel interventions
Gunning, F. M., Oberlin, L. E., Schier, M. M., & Victoria, L. W. (2021) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2021.05.002 · Cited by 54
Statins in the treatment of depression: Hype or hope?
Köhler-Forsberg, O., Otte, C., Gold, S. M., & Østergaard, S. D. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107625 · Cited by 51
Unpacking Major Depressive Disorder: From Classification to Treatment Selection
Kennedy, S. H., & Ceniti, A. K. (2017) · The Canadian Journal of Psychiatry · doi:10.1177/0706743717748883 · Cited by 52
Fabbri, C., Tansey, K. E., Perlis, R. H., Hauser, J., Henigsberg, N., Maier, W., Mors, O., Placentino, A., Rietschel, M., Souery, D., et al. (2018) · The Pharmacogenomics Journal · doi:10.1038/tpj.2017.44 · Cited by 49
Medeiros, G. C., Rush, A. J., Jha, M. K., Carmody, T. J., Furman, J. L., Czysz, A. H., Trombello, J. M., Cooper, C. M., & Trivedi, M. H. (2020) · Depression and Anxiety · doi:10.1002/da.23006 · Cited by 52
Self-citationPredicting and Managing Treatment Non-response in Posttraumatic Stress Disorder
Fonzo, G. A., Federchenco, V., & Lara, A. (2020) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-020-00203-1 · Cited by 44
Fee, C., Prevot, T. D., Misquitta, K., Knutson, D. E., Li, G., Mondal, P., Cook, J. M., Banasr, M., & Sibille, E. (2021) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab002 · Cited by 45
A Novel Framework for Network-Targeted Neuropsychiatric Deep Brain Stimulation
Allawala, A. B., Bijanki, K. R., Goodman, W. K., Cohn, J. F., Viswanathan, A., Yoshor, D., Borton, D. A., Pouratian, N., & Sheth, S. A. (2021) · Neurosurgery · doi:10.1093/neuros/nyab112 · Cited by 52
Gunning, F. M., Anguera, J. A., Victoria, L. W., & Areán, P. A. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01386-8 · Cited by 52
Gavin, N. I., Meltzer‐Brody, S., Glover, V., & Gaynes, B. N. (2015) · Identifying Perinatal Depression and Anxiety · doi:10.1002/9781118509722.ch1 · Cited by 33
Self-citationA Review of Antidepressant Therapy in Primary Care: Current Practices and Future Directions
Kennedy, S. H. (2013) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.12r01420 · Cited by 41
Husain, M. I., Ledwos, N., Fellows, E., Baer, J., Rosenblat, J. D., Blumberger, D. M., Mulsant, B. H., & Castle, D. J. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1076459 · Cited by 50
Pharmacologic Treatment of Perinatal Depression
Kimmel, M., Cox, E., Schiller, C. E., Gettes, E., & Meltzer-Brody, S. E. (2018) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2018.04.007 · Cited by 51
A Structured Approach to Detecting and Treating Depression in Primary Care: VitalSign6 Project
Jha, M. K., Grannemann, B. D., Trombello, J. M., Clark, E. W., Levinson, S., Lawson, T., Greer, T. L., Rush, A. J., & Trivedi, M. H. (2019) · The Annals of Family Medicine · doi:10.1370/afm.2418 · Cited by 50
Self-citationJoyce, J. B., Grant, C. W., Liu, D., MahmoudianDehkordi, S., Kaddurah‐Daouk, R., Skime, M. K., Biernacka, J. M., Frye, M. A., Mayes, T. L., Carmody, T. J., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01632-z · Cited by 51
Self-citationCooper, M. D., Rosenblat, J. D., Cha, D. S., Lee, Y., Kakar, R., & McIntyre, R. S. (2017) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2016.1139747 · Cited by 41
Trivedi, M., Jha, M., Kahalnik, F., Pipes, R., Levinson, S., Lawson, T., Rush, A., Trombello, J., Grannemann, B., Tovian, C., et al. (2019) · Pharmaceuticals · doi:10.3390/ph12020071 · Cited by 49
“This contention is supported by our prior work that has shown that treatment outcomes are comparable between primary and psychiatric care settings under pragmatic trial conditions [40,41].”
ResultSelf-citationKim, N., Cho, S., Kim, H.-Y., Kim, S. H., Lee, H. J., Park, C. H. K., Rhee, S. J., Kim, D.-W., Yang, B. R., Choi, S., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0221552 · Cited by 48
Shan, X., Zhao, W., Qiu, Y., Wu, H., Chen, J., Fang, Y., Guo, W., & Li, L. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00960 · Cited by 48
Huneke, N. T. M., Amin, J., Baldwin, D. S., Bellato, A., Brandt, V. C., Chamberlain, S. R., Correll, C. U., Eudave, L., Garner, M. J., Gosling, C. J., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02638-x · Cited by 47
Rapid infusion of esketamine for unipolar and bipolar depression: a retrospective chart review
S Correia-Melo, F., C Argolo, F., Araújo-de-Freitas, L., Carneiro Gomes Leal, G., Kapczinski, F., L Lacerda, A., & C Quarantini, L. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s135623 · Cited by 43
Rymaszewska, J., Lion, K., Pawlik-Sobecka, L., Pawłowski, T., Szcześniak, D. M., Trypka, E., Rymaszewska, J. E., Zabłocka, A., & Stańczykiewicz, B. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00522 · Cited by 47
Caspani, G., Turecki, G., Lam, R. W. M., Milev, R. V., Frey, B. N., MacQUEEN, G. M., Müller, D. J., Rotzinger, S., Kennedy, S. H., Foster, J. A., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02421-6 · Cited by 47
Digital Phenotyping for Differential Diagnosis of Major Depressive Episode: Narrative Review
Ettore, É., Müller, P., Hinze, J., Riemenschneider, M. J., Benoît, M., Giordana, B., Postin, D., Hurlemann, R., Lecomte, A., Musiol, M., et al. (2023) · JMIR Mental Health · doi:10.2196/37225 · Cited by 48
Suzuki, A., Hara, H., & Kimura, H. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109308 · Cited by 46
“Moreover, the therapeutic onset of action is delayed by several weeks (Gaynes et al., 2009).”
BackgroundPersonalizing antidepressant choice by sex, body mass index, and symptom profile: An iSPOT-D report
Green, E., Goldstein‐Piekarski, A. N., Schatzberg, A. F., Rush, A. J., Ma, J., & Williams, L. M. (2016) · Personalized Medicine in Psychiatry · doi:10.1016/j.pmip.2016.12.001 · Cited by 46
Self-citationSahib, A. K., Loureiro, J. R. A., Vasavada, M. M., Kubicki, A., Joshi, S. H., Wang, K., Woods, R. P., Congdon, E., Wang, D. J. J., Boucher, M. L., et al. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.01.017 · Cited by 43
Popescu, C., Golden, G. M., Benrimoh, D. A., Tanguay-Sela, M., Slowey, D., Lundrigan, E., Williams, J. D., Desormeau, B., Kardani, D., Pérez, T., et al. (2021) · JMIR Formative Research · doi:10.2196/31862 · Cited by 46
Guest, F. L., Guest, P. C., & Martins‐de‐Souza, D. (2016) · Biomarkers in Medicine · doi:10.2217/bmm-2015-0055 · Cited by 47
Increased Aperiodic Neural Activity During Sleep in Major Depressive Disorder
Rosenblum, Y., Bovy, L., Weber, F. D., Steiger, A., Zeising, M., & Dresler, M. (2022) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2022.10.001 · Cited by 45
Ermers, N. J., Hagoort, K., & Scheepers, F. E. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00472 · Cited by 44
Corponi, F., Anmella, G., Verdolini, N., Pacchiarotti, I., Samalin, L., Popović, D., Azorin, J., Angst, J., Bowden, C. L., Mosolov, S. N., et al. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.03.017 · Cited by 43
Star-D: lessons learned and future implications
Rush, A. J. (2011) · Depression and Anxiety · doi:10.1002/da.20841 · Cited by 43
Self-citationCurcumin as a putative antidepressant
Seo, H., Wang, S., Han, C., Lee, S.-J., Patkar, A. A., Masand, P. S., & Pae, C. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1008457 · Cited by 43
Braun, D., Rosenberg, A. M., Rabaniam, E., Haruvi, R., Malamud, D., Barbara, R., Aiznkot, T., Levavi‐Sivan, B., & Kawashima, T. (2024) · Molecular Psychiatry · doi:10.1038/s41380-023-02391-7 · Cited by 41
Cosci, F., & Chouinard, G. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813333-0.00007-x · Cited by 41
Sakurai, H., Yonezawa, K., Tani, H., Mimura, M., Bauer, M., & Uchida, H. (2022) · Pharmacopsychiatry · doi:10.1055/a-1714-9097 · Cited by 42
Self-selected intensity exercise in the treatment of major depression: A pragmatic RCT
Doose, M., Ziegenbein, M., Hoos, O., Reim, D., Stengert, W., Hoffer, N., Vogel, C., Ziert, Y., & Sieberer, M. (2015) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651501.2015.1082599 · Cited by 28
Multiple-therapy-resistant major depressive disorder: a clinically important concept
McAllister-Williams, R. H., Christmas, D. M. B., Cleare, A. J., Currie, A., Gledhill, J., Insole, L., Malizia, A. L., McGeever, M., Morriss, R., Robinson, L. J., et al. (2018) · British Journal of Psychiatry · doi:10.1192/bjp.2017.33 · Cited by 40
The Role of Glutamate Underlying Treatment-resistant Depression
Kim, J., Kim, T.-E., Lee, S., & Koo, J. W. (2023) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.22.1034 · Cited by 41
Sahib, A. K., Loureiro, J. R., Vasavada, M. M., Kubicki, A., Wade, B., Joshi, S. H., Woods, R. P., Congdon, E., Espinoza, R., & Narr, K. L. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-00947-7 · Cited by 38
SIRT1 and SIRT2 Modulators: Potential Anti-Inflammatory Treatment for Depression?
Zhang, Y., Anoopkumar‐Dukie, S., & Davey, A. K. (2021) · Biomolecules · doi:10.3390/biom11030353 · Cited by 40
Zhang, Y., Anoopkumar‐Dukie, S., Mallik, S. B., & Davey, A. K. (2021) · Journal of Neural Transmission · doi:10.1007/s00702-021-02331-1 · Cited by 40
Mishra, P. K., Kumar, A., Behar, K. L., & Patel, A. B. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14544 · Cited by 39
Use of Buprenorphine in treatment of refractory depression—A review of current literature
Stanciu, C. N., Glass, O., & Penders, T. M. (2017) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2017.01.015 · Cited by 39
Luo, D., Ma, R., Wu, Y., Zhang, X., Liu, Y., Wang, L., & Fu, W. (2017) · Medical Science Monitor · doi:10.12659/msm.902549 · Cited by 35
Herzog, D. P., Wegener, G., Lieb, K., Müller, M. B., & Treccani, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040949 · Cited by 39
Lee, J., Lee, S.-B., Kim, D. W., Shin, N., Jeong, S.-J., Yang, C. H., & Son, C. (2021) · Science Advances · doi:10.1126/sciadv.abj3400 · Cited by 39
Psilocybin Efficacy and Mechanisms of Action in Major Depressive Disorder: a Review
Prouzeau, D., Conejero, I., Voyvodic, P. L., Bécamel, C., Abbar, M., & López‐Castromán, J. (2022) · Current Psychiatry Reports · doi:10.1007/s11920-022-01361-0 · Cited by 40
Mosqueiro, B. P., Caldieraro, M. A., Messinger, M. F., da Costa, F. B. P., Peteet, J. R., & Fleck, M. P. D. A. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.10.028 · Cited by 38
Difrancesco, S., Penninx, B. W. J. H., Antypa, N., van Hemert, A. M., Riese, H., & Lamers, F. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.01.052 · Cited by 39
Ma, K., Zhang, H., Wei, G., Dong, Z., Zhao, H., Han, X., Song, X., Zhang, H., Zong, X., Baloch, Z., et al. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s200264 · Cited by 37
Distinguishing features of depression in dementia from primary psychiatric disease
Fisher, D. W., Dunn, J. T., & Dong, H. (2024) · Discover Mental Health · doi:10.1007/s44192-023-00057-y · Cited by 36
Therapeutic Potential and Limitation of Serotonin Type 7 Receptor Modulation
Fukuyama, K., Motomura, E., & Okada, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032070 · Cited by 36
Treatment Decisions Based on Scalar and Functional Baseline Covariates
Ciarleglio, A., Petkova, E., Ogden, R. T., & Tarpey, T. (2015) · Biometrics · doi:10.1111/biom.12346 · Cited by 36
Anti-depressant effects of oil from fructus gardeniae via PKA-CREB-BDNF signaling
Ruan, J., Liu, L., Shan, X., Xia, B., & Fu, Q. (2019) · Bioscience Reports · doi:10.1042/bsr20190141 · Cited by 37
Yang, L., Huang, Y., Chen, F., Wang, Y., Su, K., Zhao, M., Tao, W., & Liu, W. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110808 · Cited by 35
Maintenance Ketamine Therapy for Treatment-Resistant Depression
Archer, S., Chrenek, C., & Swainson, J. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000894 · Cited by 34
Treating major depression and comorbid disorders with transcranial magnetic stimulation
Thompson, L. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.07.025 · Cited by 35
Difrancesco, S., Penninx, B. W. J. H., Riese, H., Giltay, E. J., & Lamers, F. (2021) · Psychological Medicine · doi:10.1017/s0033291720004870 · Cited by 35
Kangas, E. S., Vuoriainen, E., Lindeman, S. M., & Astikainen, P. (2022) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2022.07.003 · Cited by 36
Metadata
- Authors
- Gaynes, B. N., Warden, D., Trivedi, M. H., Wisniewski, S. R., Fava, M., & Rush, A. J.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- The University of Texas Southwestern Medical Center (US)
- University of Pittsburgh (US)
- National University of Singapore (SG)
- Venue
- Psychiatric Services
- Published
- 2009-11
- Volume
- 60
- Issue
- 11
- Pages
- 1439-1445
- ISSN
- 0022-1597 (ISSN-L)
- 1075-2730
- 1557-9700
- OpenAlex
- W2095852687
- Cited by
- 661
- References
- 0
- Citations by year
- 2026: 37 · 2025: 47 · 2024: 57 · 2023: 73 · 2022: 61 · 2021: 58 · 2020: 55 · 2019: 48 · 2018: 41 · 2017: 42 · 2016: 28 · 2015: 33 · 2014: 20 · 2013: 20 · 2012: 16
- FWCI
- 9.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Psychiatric Services (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Funders
- University of Texas Southwestern Medical Center
- National Institutes of Health (n01mh90003-26-0-0)
- National Institute of Mental Health (N01‐MH‐90003)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Keywords
- STAR*D, major depressive disorder, antidepressant treatment, treatment-resistant depression, remission, citalopram, antidepressant switching, antidepressant augmentation, primary care, psychiatric clinic
- MeSH terms
- Venlafaxine Hydrochloride, Adolescent, Adult, Aged, Cyclohexanols, Major Depressive Disorder, Female, Humans, Male, Middle Aged, Primidone, Remission Induction, Time Factors, Citalopram, Cognitive Behavioral Therapy, Bupropion, Treatment Outcome, Treatment Failure, Selective Serotonin Reuptake Inhibitors, Dopamine Uptake Inhibitors, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.